Cancer Letters
Volume 286, Issue 2 , Pages 154-160 , 28 December 2009

Peroxiredoxins, a novel target in cancer radiotherapy

  • Bo Zhang

      Affiliations

    • Department of Medical Genetics, Third Military Medical University, Chongqing 400038, China
    • Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing 400038, China
    • ,
  • Yan Wang

      Affiliations

    • Department of Medical Genetics, Third Military Medical University, Chongqing 400038, China
    • ,
  • Yongping Su

      Affiliations

    • Institute of Combined Injury, State Key Laboratory of Trauma, Burns and Combined Injury, Third Military Medical University, Chongqing 400038, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 23 68752279; fax: +86 23 65318610.

Received 24 March 2009 ,Revised 29 April 2009 ,Accepted 30 April 2009.

References 

  1. Blanchetot C, Boonstra J. The ROS-NOX connection in cancer and angiogenesis. Crit. Rev. Eukaryot. Gene Expr. 2008;18:35–45
  2. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science. 2003;300:650–653
  3. Rhee SG, Jeong W, Chang TS, Woo HA. Sulfiredoxin, the cysteine sulfinic acid reductase specific to 2-Cys peroxiredoxin: its discovery, mechanism of action, and biological significance. Kidney Int. Suppl. 2007;106:S3–S8
  4. Lawenda BD, Kelly KM, Ladas EJ, Sagar SM, Vickers A, Blumberg JB. Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?. J. Natl. Cancer Inst. 2008;100:773–783
  5. Okunieff P, Swarts S, Keng P, et al. Antioxidants reduce consequences of radiation exposure. Adv. Exp. Med. Biol. 2008;614:165–178
  6. Kim K, Kim IH, Lee KY, Rhee SG, Stadtman ER. The isolation, purification of a specific “Protector” protein which inhibits enzyme inactivation by a thiol/Fe(III)/O2 mixed-function oxidation system. J. Biol. Chem. 1988;263:4704–4711
  7. Knoops B, Loumaye E, Van der Eecken V. Evolution of the peroxiredoxins. Subcell. Biochem. 2007;44:27–40
  8. Dietz KJ. The dual function of plant peroxiredoxins in antioxidant defence and redox signaling. Subcell. Biochem. 2007;44:267–294
  9. Link AJ, Robison K, Church GM. Comparing the predicted and observed properties of proteins encoded in the genome of Escherichia coli K-12. Electrophoresis. 1997;18:1259–1313
  10. Tavender TJ, Sheppard AM, Bulleid NJ. Peroxiredoxin IV is an endoplasmic reticulum-localized enzyme forming oligomeric complexes in human cells. Biochem. J. 2008;411:191–199
  11. Nguyên-Nhu NT, Berck J, Clippe A, et al. Human peroxiredoxin 5 gene organization, initial characterization of its promoter and identification of alternative forms of mRNA. Biochim. Biophys. Acta. 2007;1769:472–483
  12. Lee W, Wells T, Kantorow M. Localization and H2O2-specific induction of PRDX3 in the eye lens. Mol. Vis. 2007;13:1469–1474
  13. Avila PC, Kropotov AV, Krutilina R, Krasnodembskay A, Tomilin NV, Serikov VB. Peroxiredoxin V contributes to antioxidant defense of lung epithelial cells. Lung. 2008;186:103–114
  14. Ishii T, Itoh K, Akasaka J, et al. Induction of murine intestinal and hepatic peroxiredoxin MSP23 by dietary butylated hydroxyanisole. Carcinogenesis. 2000;21:1013–1016
  15. Wijayanti N, Naidu S, Kietzmann T, Immenschuh S. Inhibition of phorbol ester-dependent peroxiredoxin I gene activation by lipopolysaccharide via phosphorylation of RelA/p65 at serine 276 in monocytes. Free Rad. Biol. Med. 2008;44:699–710
  16. Immenschuh S, Iwahara S, Schwennen B. Induction of heme-binding protein 23/ peroxiredoxin I gene expression by okadaic acid in cultured rat hepatocytes. DNA Cell Biol. 2002;21:347–354
  17. Rhee SG, Chae HZ, Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Rad. Biol. Med. 2005;38:1543–1552
  18. Rhee SG. Cell signaling. H2O2, a necessary evil for cell signaling. Science. 2006;312:1882–1883
  19. Yanagawa T, Ishikawa T, Ishii T, et al. Peroxiredoxin I expression in human thyroid tumors. Cancer Lett. 1999;145:127–132
  20. Yanagawa T, Iwasa S, Ishii T, et al. Peroxiredoxin I expression in oral cancer: a potential new tumor marker. Cancer Lett. 2000;156:27–35
  21. Chang JW, Jeon HB, Lee JH, et al. Augmented expression of peroxiredoxin I in lung cancer. Biochem. Biophys. Res. Commun. 2001;289:507–512
  22. Kim HJ, Chae HZ, Kim YJ, et al. Preferential elevation of Prx I and Trx expression in lung cancer cells following hypoxia and in human lung cancer tissues. Cell Biol. Toxicol. 2003;19:285–298
  23. Lehtonen ST, Svensk AM, Soini Y, et al. Peroxiredoxins, a novel protein family in lung cancer. Int. J. Cancer. 2004;111:514–521
  24. Alfonso P, Catalá M, Rico-Morales ML, et al. Proteomics analysis of lung biopsies: differential protein expression profile between peritumoral and tumoral tissue. Proteomics. 2004;4:442–447
  25. Park JH, Kim YS, Lee HL, et al. Expression of peroxiredoxin and thioredoxin in human lung cancer and paired normal lung. Respirology. 2006;11:269–275
  26. Kim JH, Bogner PN, Ramnath N, Park Y, Yu J, Park YM. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin. Cancer Res. 2007;13:3875–3882
  27. Kim JH, Bogner PN, Baek SH, et al. Up-regulation of peroxiredoxin 1 in lung cancer and its implication as a prognostic and therapeutic target. Clin. Cancer Res. 2008;14:2326–2333
  28. Chang JW, Lee SH, Jeong JY, et al. Peroxiredoxin-I is an autoimmunogenic tumor antigen in non-small cell lung cancer. FEBS Lett. 2005;579:2873–2877
  29. Quan C, Cha EJ, Lee HL, Han KH, Lee KM, Kim WJ. Enhanced expression of peroxiredoxin I and VI correlates with development, recurrence and progression of human bladder cancer. J. Urol. 2006;175:1512–1516
  30. Iwao-Koizumi K, Matoba R, Ueno N, et al. Prediction of docetaxel response in human breast cancer by gene expression profiling. J. Clin. Oncol. 2005;23:22–31
  31. Qi Y, Chiu JF, Wang L, Kwong DL, He QY. Comparative proteomic analysis of esophageal squamous cell carcinoma. Proteomics. 2005;5:2960–2971
  32. Shen J, Person MD, Zhu J, Abbruzzese JL, Li D. Protein expression profiles in pancreatic adenocarcinoma compared with normal pancreatic tissue and tissue affected by pancreatitis as detected by two-dimensional gel electrophoresis and mass spectrometry. Cancer Res. 2004;64:9018–9026
  33. Kinnula VL, Lehtonen S, Sormunen R, et al. Overexpression of peroxiredoxins I, II, III, V, and VI in malignant mesothelioma. J. Pathol. 2002;196:316–323
  34. Yanagawa T, Omura K, Harada H, et al. Peroxiredoxin I expression in tongue squamous cell carcinomas as involved in tumor recurrence. Int. J. Oral Maxillofac. Surg. 2005;34:915–920
  35. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA, Chae HZ. Overexpression of peroxiredoxin in human breast cancer. Anticancer Res. 2001;21:2085–2090
  36. Kim YJ, Ahn JY, Liang P, Ip C, Zhang Y, Park YM. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 2007;67:546–554
  37. Lee W, Choi KS, Riddell J, et al. Human peroxiredoxin 1 and 2 are not duplicate proteins: the unique presence of CYS83 in Prx1 underscores the structural and functional differences between Prx1 and Prx2. J. Biol. Chem. 2007;282:22011–22022
  38. Li Y, Qin X, Cui J, et al. Proteome analysis of aflatoxin B(1)-induced hepatocarcinogenesis in tree shrew (Tupaia belangeri chinensis) and functional identification of candidate protein peroxiredoxin II. Proteomics. 2008;8:1490–1501
  39. Memon AA, Chang JW, Oh BR, Yoo YJ. Identification of differentially expressed proteins during human urinary bladder cancer progression. Cancer Detect. Prev. 2005;29:249–255
  40. Carta F, Demuro PP, Zanini C, et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res. 2005;15:235–244
  41. Furuta J, Nobeyama Y, Umebayashi Y, Otsuka F, Kikuchi K, Ushijima T. Silencing of Peroxiredoxin 2 and aberrant methylation of 33 CpG islands in putative promoter regions in human malignant melanomas. Cancer Res. 2006;66:6080–6086
  42. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL, Soini Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 2003;9:3418–3424
  43. Choi JH, Kim TN, Kim S, et al. Overexpression of mitochondrial thioredoxin reductase and peroxiredoxin III in hepatocellular carcinomas. Anticancer Res. 2002;22:3331–3335
  44. Smith L, Welham KJ, Watson MB, Drew PJ, Lind MJ, Cawkwell L. The proteomic analysis of cisplatin resistance in breast cancer cells. Oncol. Res. 2007;16:497–506
  45. Lin JF, Xu J, Tian HY, et al. Identification of candidate prostate cancer biomarkers in prostate needle biopsy specimens using proteomic analysis. Int. J. Cancer. 2007;121:2596–2605
  46. Chung JC, Oh MJ, Choi SH, Bae CD. Proteomic analysis to identify biomarker proteins in pancreatic ductal adenocarcinoma. ANZ J. Surg. 2008;78:245–251
  47. Khalil AA. Biomarker discovery: a proteomic approach for brain cancer profiling. Cancer Sci. 2007;98:201–213
  48. Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome profile of stomach cancer: identification of the biomarker candidates. Oncol. Res. 2004;14:491–499
  49. Fujita Y, Nakanishi T, Hiramatsu M, et al. Proteomics-based approach identifying autoantibody against peroxiredoxin VI as a novel serum marker in esophageal squamous cell carcinoma. Clin. Cancer Res. 2006;12:6415–6420
  50. Park CK, Kim JH, Moon MJ, et al. Investigation of molecular factors associated with malignant transformation of oligodendroglioma by proteomic study of a single case of rapid tumor progression. J. Cancer Res. Clin. Oncol. 2008;134:255–262
  51. Li DQ, Wang L, Fei F, et al. Identification of breast cancer metastasis- associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography–ion trap-mass spectrometry. Proteomics. 2006;6:3352–3368
  52. Chang XZ, Li DQ, Hou YF, et al. Identification of the functional role of peroxiredoxin 6 in the progression of breast cancer. Breast Cancer Res. 2007;9:R76
  53. Park SH, Chung YM, Lee YS, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin. Cancer Res. 2000;6:4915–4920
  54. Chen WC, McBride WH, Iwamoto KS, et al. Induction of radioprotective peroxiredoxin-I by ionizing irradiation. J. Neurosci. Res. 2002;70:794–798
  55. Zhang B, Su Y, Ai G, Wang Y, Wang T, Wang F. Involvement of peroxiredoxin I in protecting cells from radiation-induced death. J. Radiat. Res. (Tokyo). 2005;46:305–312
  56. Miura Y, Kano M, Yamada M, et al. Proteomic study on X-irradiation-responsive proteins and ageing: search for responsible proteins for radiation adaptive response. J. Biochem. 2007;142:145–155
  57. Lee K, Park JS, Kim YJ, et al. Differential expression of Prx I and II in mouse testis and their up-regulation by radiation. Biochem. Biophys. Res. Commun. 2002;296:337–342
  58. Ao X, Lubman DM, Davis MA, et al. Comparative proteomic analysis of radiation-induced changes in mouse lung: fibrosis-sensitive and -resistant strains. Radiat. Res. 2008;169:417–425
  59. An JH, Kim J, Seong J. Redox signaling by ionizing radiation in mouse liver. Ann. NY Acad. Sci. 2004;1030:86–94
  60. Chen C, Lorimore SA, Evans CA, Whetton AD, Wright EG. A proteomic analysis of murine bone marrow and its response to ionizing radiation. Proteomics. 2005;5:4254–4263
  61. An JH, Seong JS. Proteomics analysis of apoptosis-regulating proteins in tissues with different radiosensitivity. J. Radiat. Res. (Tokyo). 2006;47:147–155
  62. Lee SC, Chae HZ, Lee JE, et al. Peroxiredoxin is ubiquitously expressed in rat skin: isotype-specific expression in the epidermis and hair follicle. J. Invest. Dermatol. 2000;115:1108–1114
  63. Di Pietro R, Fang H, Fields K, et al. Peroxiredoxin genes are not induced in myeloid leukemia cells exposed to ionizing radiation. Int. J. Immunopathol. Pharmacol. 2006;19:517–524
  64. Chen C, Boylan MT, Evans CA, Whetton AD, Wright EG. Application of two-dimensional difference gel electrophoresis to studying bone marrow macrophages and their in vivo responses to ionizing radiation. J. Proteome Res. 2005;4:1371–1380
  65. Wang T, Tamae D, LeBon T, Shively JE, Yen Y, Li JJ. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res. 2005;65:10338–10346
  66. Lee YS, Chang HW, Jeong JE, Lee SW, Kim SY. Proteomic analysis of two head and neck cancer cell lines presenting different radiation sensitivity. Acta. Otolaryngol. 2008;128:86–92
  67. Park JJ, Chang HW, Jeong EJ, et al. Peroxiredoxin IV protects cells from radiation-induced apoptosis in head-and-neck squamous cell carcinoma. Int. J. Radiat. Oncol. Biol. Phys. 2009;73:1196–1202
  68. Kropotov AV, Grudinkin PS, Pleskach NM, Gavrilov BA, Tomilin NV, Zhivotovsky B. Downregulation of peroxiredoxin V stimulates formation of etoposide-induced double-strand DNA breaks. FEBS Lett. 2004;572:75–79
  69. Kropotov A, Gogvadze V, Shupliakov O, et al. Peroxiredoxin V is essential for protection against apoptosis in human lung carcinoma cells. Exp. Cell Res. 2006;312:2806–2815
  70. Kim YJ, Lee WS, Ip C, Chae HZ, Park EM, Park YM. Prx1 suppresses radiation-induced c-Jun NH2-terminal kinase signaling in lung cancer cells through interaction with the glutathione S-transferase Pi/c-Jun NH2-terminal kinase complex. Cancer Res. 2006;66:7136–7142
  71. Kang SW, Chang TS, Lee TH, Kim ES, Yu DY, Rhee SG. Cytosolic peroxiredoxin attenuates the activation of Jnk and p38 but potentiates that of Erk in Hela cells stimulated with tumor necrosis factor-alpha. J. Biol. Chem. 2004;279:2535–2543
  72. Chen MF, Keng PC, Shau H, et al. Inhibition of lung tumor growth and augmentation of radiosensitivity by decreasing peroxiredoxin I expression. Int. J. Radiat. Oncol. Biol. Phys. 2006;64:581–591
  73. Zhang B, Wang Y, Liu K, et al. Adenovirus-mediated transfer of siRNA against peroxiredoxin I enhances the radiosensitivity of human intestinal cancer. Biochem. Pharmacol. 2008;75:660–667
  74. Yo YD, Chung YM, Park JK, Ahn CM, Kim SK, Kim HJ. Synergistic effect of peroxiredoxin II antisense on cisplatin-induced cell death. Exp. Mol. Med. 2002;34:273–277
  75. Kattan Z, Minig V, Leroy P, Dauça M, Becuwe P. Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells. Breast Cancer Res. Treat. 2008;108:203–215

PII: S0304-3835(09)00324-3

doi: 10.1016/j.canlet.2009.04.043

Cancer Letters
Volume 286, Issue 2 , Pages 154-160 , 28 December 2009

Article Tools

* Image Usage & Resolution